Moderna

NASDAQ:MRNABiotech

Cambridge, Massachusetts, United States · Est. 2010 · 2,500 employees

Moderna is a biotechnology company that develops mRNA-based therapeutics and vaccines for infectious diseases, oncology, and rare diseases.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

123

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

16 drugs in development

Phase 32

Phase 26

Phase 17

Preclinical2

By Therapeutic Area

top 4

Infectious Disease

739%

Oncology

422%

Neurology

16%

Metabolic & Endocrine

16%

R&D Momentum

66/100

Pipeline Velocity

34/100

Trial Completion Rate

89/100

Pipeline Concentration

28/100

Pipeline Freshness

73/100

Strategic Signals

↗Active in Neurology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Oct 30, 2026

Recruiting

A Phase 2, Randomized, Observer-Blind, Dose Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age

Oct 29, 2026

Recruiting

A Phase 1, Dose-escalation, Blinded Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children (9 to <18 Years of Age)

Oct 28, 2026

Recruiting

A Phase 3b/4, Open-label Study to Assess the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

Oct 24, 2026

Completed

A Phase 1/2, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Earlier

Oct 21, 2026TrialA Phase 3b/4 Study to Assess the Immunogenicity and Safety of Updated mRNA Seasonal Influenza Vaccine Compositions

Oct 14, 2026TrialA Phase 1, Open-label, Multicenter, Dose-escalation Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

Oct 9, 2026TrialA Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity in Relation to the Product Attributes of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Adults ≥50 to <65 Years of Age

Sep 30, 2026TrialA Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥60 Years of Age

4 more events

Sep 29, 2026TrialA Phase 4, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of mRNA-1283 And mRNA-1273 Variant-Containing Formulation in Adults 50 to 64 Years of Age Without Underlying Conditions That Put Them at High Risk for Severe Outcomes From COVID-19

Sep 25, 2026TrialA Phase 1, Observer-Blind, Placebo-Controlled, Dose-Escalation Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants 18 to 65 Years of Age

Sep 24, 2026TrialA Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Sep 17, 2026TrialA Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared With a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age

Details